Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$779.00K$779.00K−69.4% vs Q2 2018 Net Income-$30.03M-$30.03MN/M vs Q2 2018 EPS Diluted-$0.20-$0.20N/M vs Q2 2018 Gross Profit$672,000−72.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$9,667,000N/M Free Cash Flowderived-$9,862,000N/M Margins · derivedGross margin86.3%−9.6 pt vs Q2 2018
Operating margin-1389.1%−1030.1 pt vs Q2 2018
Net margin-3855.2%−3689.7 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 8, 2019 · 39 d after period end